Table 1 Systemic levels of TNF-α, IL-1, IL-6, IL-17, and s-TLR4.
From: Deregulation of TLR4 signaling pathway characterizes Bicuspid Aortic valve syndrome
Systemic molecules examined | BAV without AAA N = 19 | BAV with AAA N = 51 | P* |
|---|---|---|---|
TNF-α (pg/ml) | 8.18 ± 1.9 | 28 ± 5.4 | <0.0001 |
IL-6 (pg/ml) | 20 ± 4.3 | 68 ± 5.6 | <0.0001 |
IL-1 (pg/ml) | 22 ± 1.4 | 55 ± 8 | <0.0001 |
IL-17 (pg/ml) | 16 ± 1.9 | 78 ± 6 | <0.0001 |
s-TLR4 (ng/ml) | 1.5 ± 1.8 | 8.5 ± 2.1 | <0.0001 |
Systemic molecules examined | TAV without AAA N = 45 | TAV with AAA N = 25 | P |
TNF-α (pg/ml) | 12.7 ± 4.3 | 75 ± 5.3 | <0.0001 |
IL-6 (pg/ml) | 28 ± 9 | 90 ± 8 | <0.0001 |
IL-1 (pg/ml) | 29 ± 6.5 | 72.4 ± 6 | <0.0001 |
IL-17 (pg/ml) | 21 ± 1.9 | 98 ± 6 | <0.0001 |
s-TLR4(ng/ml) | 4.5 ± 1.5 | 18 ± 4 | <0.0001 |
Systemic molecules examined | BAV without AAA N = 19 | TAV without AAA N = 45 | P |
TNF-α (pg/ml) | 8.18 ± 1.9 | 12.7 ± 4.3 | 0.01 |
IL-6 (pg/ml) | 20 ± 4.3 | 28 ± 9 | 0.01 |
IL-1 (pg/ml) | 22 ± 1.4 | 29 ± 6.5 | 0.01 |
IL-17 (pg/ml) | 16 ± 1.9 | 21 ± 1.9 | 0.01 |
s-TLR4 (ng/ml) | 1.5 ± 1.8 | 4.5 ± 1.5 | 0.01 |
Systemic molecules examined | BAV with AAA N = 51 | TAV with AAA N = 25 | P |
TNF-α (pg/ml) | 28 ± 5.4 | 75 ± 5.3 | 0.0001 |
IL-6 (pg/ml) | 68 ± 5.6 | 90 ± 8 | 0.001 |
IL-1 (pg/ml) | 55 ± 8 | 72.4 ± 6 | 0.001 |
IL-17 (pg/ml) | 78 ± 6 | 98 ± 6 | 0.001 |
s-TLR4(ng/ml) | 8.5 ± 2.1 | 18 ± 4 | 0.001 |
